#co-pay

This ruling will affect millions and erect barriers to care, say patient advocacy groups representing those with cancer, HIV and more.

The Texas ruling builds on a case in which a plaintiff objected, on religious grounds, to providing free HIV prevention PrEP to employees.

The attorneys general urge the CDC to create a unique billing code for PrEP to halt incorrect co-pays and charges.

The ruling centered on PrEP as HIV prevention but could apply to cancer screenings and other services and drugs.

Insurers should allow co-pay assistance to count as out-of-pocket spending, claims HHS lawsuit by HIV, hepatitis and diabetes advocates.

Some 100 million people—including 41% of U.S. adults—have health care debt, according to a recent KFF survey.

But advocates will need to press state Medicaid and insurance officials to ensure the rule is implemented.

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

During the COVID-19 crisis, some insurers are relaxing their refill rules and allowing 90-day supplies of meds to be prescribed.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.

Insurance companies can no longer implement harmful co-pay accumulator policies.

Pharma sets the prices for HIV and hep C drugs very high. What happens to those prices along the supply chain?